LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
NCT06632457 on ClinicalTrials.gov · last registry update 2026-10-14
An unusually large phase 3: 1,590 participants, more than double the 424 typical for the stage. Due to report 5 June 2029. Sponsors move these dates routinely; any movement since this site started watching is listed below. survodutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- RECRUITING
- Phase
- P3
- Drug
- survodutide
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry
- Enrollment
- 1,590
- Started
- 2024-11-12
- Primary completion
- 2029-06-05 estimated
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Time to first occurrence of any component of the composite clinical endpoint (at EoS) consisting of: all-cause mortality, liver transplant, hepatic decompensation events, worsening of MELD score to ≥15 and progression to CSPH
Conditions studied
Metabolic Dysfunction Associated Steatohepatitis
Every field above is taken directly from the registry record. See all detected changes across the class, or the survodutide page for this molecule’s full trial and approval history.